Key Insights
The global antipsychotic drugs market, valued at approximately $25 billion in 2025, is projected to experience robust growth, driven by the increasing prevalence of mental health disorders like schizophrenia, bipolar disorder, and dementia. A compound annual growth rate (CAGR) of 5.60% from 2025 to 2033 suggests a market exceeding $40 billion by the end of the forecast period. This expansion is fueled by several key factors: the rising geriatric population (increasing susceptibility to dementia and related conditions), improved diagnostic capabilities leading to earlier treatment interventions, and the ongoing development of newer, more effective atypical antipsychotics with reduced side effects. The market is segmented by application (schizophrenia holding the largest share, followed by bipolar disorder and dementia) and drug classification (with atypical antipsychotics exhibiting higher growth due to their superior efficacy and tolerability profile). While the market faces restraints such as potential side effects associated with some drugs, high treatment costs, and the ongoing challenges in managing treatment adherence, the overall outlook remains positive, driven by substantial unmet medical needs and increasing investments in research and development within the pharmaceutical sector.
The competitive landscape is intensely competitive, with major players including Eli Lilly and Company, Sumitomo Pharma Co Ltd, H Lundbeck A/S, Alkermes, Acadia Pharmaceuticals Inc, and others continuously striving to enhance their product portfolios and expand their global reach. Strategic partnerships, mergers, and acquisitions are also expected to shape the market dynamics. Geographical analysis shows North America and Europe currently dominate the market share, but regions such as Asia Pacific are exhibiting substantial growth potential due to rising healthcare expenditure and increasing awareness regarding mental health. Continued research into personalized medicine approaches and the development of novel antipsychotic agents promise to further revolutionize treatment strategies and drive market growth in the coming years.
This comprehensive report provides a detailed analysis of the global antipsychotic drugs market, covering the period 2019-2033. We delve into market dynamics, key segments, leading players, and future growth opportunities, offering actionable insights for industry stakeholders. The report utilizes data from 2019-2024 (Historical Period) with a base year of 2025 and forecasts extending to 2033 (Forecast Period). The Estimated Year for key metrics is 2025. The global market size is projected to reach xx Million by 2033.

Antipsychotic Drugs Industry Market Concentration & Dynamics
The global antipsychotic drugs market exhibits a moderately concentrated landscape, with a few major players holding significant market share. Market share data for 2025 estimates that Eli Lilly and Company holds approximately xx%, followed by Otsuka Pharmaceutical Co Ltd at xx%, and Pfizer Inc at xx%. The remaining share is distributed among other key players like AstraZeneca plc, Johnson & Johnson, and AbbVie Inc.
Market Dynamics:
- Innovation Ecosystem: Significant R&D investment drives innovation, focusing on novel drug mechanisms and improved delivery systems to address unmet patient needs and side effects associated with existing treatments.
- Regulatory Frameworks: Stringent regulatory approvals impact market entry and product lifecycles. Changes in regulatory landscapes across different regions influence market access and pricing strategies.
- Substitute Products: While limited, alternative therapeutic approaches such as psychotherapy and lifestyle modifications compete with antipsychotic drugs, particularly in milder cases of mental illness.
- End-User Trends: Growing awareness of mental health issues and increasing adoption of early interventions fuel market growth. However, concerns regarding side effects and long-term efficacy influence patient choices.
- M&A Activities: The number of M&A deals in the antipsychotic drugs market averaged xx per year between 2019 and 2024, reflecting strategic alliances and consolidation within the industry. These activities enhance research capabilities and broaden product portfolios.
Antipsychotic Drugs Industry Insights & Trends
The global antipsychotic drugs market witnessed robust growth during the historical period (2019-2024), driven by factors like the rising prevalence of schizophrenia, bipolar disorder, and other mental illnesses. The market size reached xx Million in 2024, exhibiting a Compound Annual Growth Rate (CAGR) of xx% during this period. The market is projected to maintain a healthy CAGR of xx% from 2025 to 2033.
Several factors contribute to this growth trajectory, including:
- Increased Prevalence of Mental Health Disorders: The global burden of mental illness continues to rise, leading to increased demand for effective treatments.
- Technological Advancements: Development of novel drug formulations and delivery systems enhances efficacy and reduces side effects, improving patient compliance.
- Evolving Consumer Behaviors: Growing awareness, reduced stigma around mental health, and greater access to healthcare services contribute to higher treatment rates.

Key Markets & Segments Leading Antipsychotic Drugs Industry
Dominant Segments:
- Application: Schizophrenia remains the largest application segment, accounting for xx% of the market in 2025, followed by Bipolar Disorder (xx%) and Others (xx%). Growth in these segments is primarily fueled by increasing prevalence rates and unmet medical needs.
- Drug Classification: Second Generation (Atypical) antipsychotics dominate the market (xx%), owing to their improved side effect profiles compared to First Generation (Typical) antipsychotics (xx%).
Drivers by Segment:
- Schizophrenia: Rising prevalence, limited treatment options for certain patient subgroups, and ongoing research into novel therapies drive growth.
- Bipolar Disorder: Increased awareness, improved diagnostic tools, and ongoing research into more effective and tolerable treatments contribute to market expansion.
- Unipolar Depression: While not as large as schizophrenia or bipolar disorder, this segment showcases growing need for effective treatment for chronic and often treatment-resistant depression.
- Dementia: This segment presents a significant but complex market, with several challenges around efficacy and tolerability.
- Other Applications: This category includes other conditions such as autism spectrum disorder and Tourette syndrome that are targeted by antipsychotic medications.
Regional Dominance: North America currently dominates the antipsychotic drugs market (xx%), driven by high healthcare expenditure and a large patient population. Europe follows closely, with a market share of xx% in 2025.
Antipsychotic Drugs Industry Product Developments
Recent years have witnessed significant advancements in antipsychotic drug development, focusing on improving efficacy, reducing side effects, and developing long-acting injectable formulations for better patient compliance. The introduction of new molecules with novel mechanisms of action is also transforming the therapeutic landscape. These advancements create competitive edges by offering superior treatment options with enhanced tolerability and efficacy profiles.
Challenges in the Antipsychotic Drugs Industry Market
The antipsychotic drugs market faces several challenges, including:
- Stringent Regulatory Approvals: The lengthy and rigorous approval processes increase the time and cost associated with bringing new drugs to market.
- High R&D Costs: Developing new antipsychotic drugs is expensive, requiring significant investment in research and clinical trials.
- Generic Competition: The entry of generic antipsychotics intensifies competition and puts downward pressure on pricing.
- Side Effect Concerns: The potential for serious side effects, such as weight gain, metabolic changes, and movement disorders, limits patient compliance and poses a major challenge.
Forces Driving Antipsychotic Drugs Industry Growth
Key growth drivers include:
- Rising Prevalence of Mental Illness: The increasing global burden of mental health disorders fuels demand for effective treatments.
- Technological Advancements: Innovations in drug delivery systems and novel drug mechanisms improve efficacy and safety.
- Increased Healthcare Spending: Rising healthcare expenditure globally enables greater access to specialized mental health services.
Long-Term Growth Catalysts in the Antipsychotic Drugs Industry
Long-term growth will be driven by continued innovation in drug development, the expansion of treatment access in emerging markets, and strategic partnerships between pharmaceutical companies and healthcare providers to improve patient care and outcomes. Furthermore, personalized medicine approaches aiming to tailor treatment to individual patient needs are expected to fuel growth.
Emerging Opportunities in Antipsychotic Drugs Industry
Emerging opportunities include:
- Personalized Medicine: Tailoring treatment based on individual genetic and clinical characteristics can optimize efficacy and minimize side effects.
- Digital Therapeutics: Integrating digital technologies into treatment pathways can improve patient engagement and treatment adherence.
- Expansion into Emerging Markets: Untapped potential exists in rapidly developing economies with growing populations and increasing awareness of mental health issues.
Leading Players in the Antipsychotic Drugs Industry Sector
- Eli Lilly and Company
- Sumitomo Pharma Co Ltd
- H Lundbeck A/S
- Alkermes
- Acadia Pharmaceuticals Inc
- GlaxoSmithKline plc
- Intra-Cellular Therapies Inc
- Teva Pharmaceutical Industries Ltd
- AstraZeneca plc
- AbbVie Inc
- Johnson & Johnson
- Otsuka Pharmaceutical Co Ltd
- Pfizer Inc
Key Milestones in Antipsychotic Drugs Industry
- January 2023: Luye Pharma Group receives FDA approval for Rykindo (Schizophrenia and bipolar 1 disorder).
- February 2022: Alkermes plc releases positive Phase 3b results for LYBALVI in schizophrenia.
- January 2022: Otsuka, Otsuka American Pharmaceutical, and Lundbeck receive FDA approval for REXULTI in adolescents with schizophrenia.
Strategic Outlook for Antipsychotic Drugs Industry Market
The antipsychotic drugs market is poised for continued growth, driven by innovation, expanding treatment access, and increasing awareness. Strategic opportunities lie in developing personalized therapies, leveraging digital technologies, and expanding into emerging markets. Companies that successfully navigate regulatory hurdles, address side effect concerns, and develop innovative treatment approaches will be well-positioned to capture market share and drive future growth.
Antipsychotic Drugs Industry Segmentation
-
1. Application
- 1.1. Schizophrenia
- 1.2. Bipolar Disorder
- 1.3. Unipolar Disorder
- 1.4. Dementia
- 1.5. Others
-
2. Drug Classification
- 2.1. First Generation (Typical)
- 2.2. Second Generation (Atypical)
Antipsychotic Drugs Industry Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. Europe
- 2.1. Germany
- 2.2. United Kingdom
- 2.3. France
- 2.4. Italy
- 2.5. Spain
- 2.6. Rest of Europe
-
3. Asia Pacific
- 3.1. China
- 3.2. Japan
- 3.3. India
- 3.4. Australia
- 3.5. South Korea
- 3.6. Rest of Asia Pacific
-
4. Middle East and Africa
- 4.1. GCC
- 4.2. South Africa
- 4.3. Rest of Middle East and Africa
-
5. South America
- 5.1. Brazil
- 5.2. Argentina
- 5.3. Rest of South America

Antipsychotic Drugs Industry REPORT HIGHLIGHTS
Aspects | Details |
---|---|
Study Period | 2019-2033 |
Base Year | 2024 |
Estimated Year | 2025 |
Forecast Period | 2025-2033 |
Historical Period | 2019-2024 |
Growth Rate | CAGR of 5.60% from 2019-2033 |
Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Rising Prevalence of Mental Disorders; Increasing Focus of Governments and Health Care Organizations on Mental Health; Constant Investment in Research and Development
- 3.3. Market Restrains
- 3.3.1. Addiction Caused Due to the Antipsychotic Drugs; Patent Expiry of Major Drugs
- 3.4. Market Trends
- 3.4.1. Schizophrenia is Expected to Hold Major Share in the Market over the Forecast Period
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Antipsychotic Drugs Industry Analysis, Insights and Forecast, 2019-2031
- 5.1. Market Analysis, Insights and Forecast - by Application
- 5.1.1. Schizophrenia
- 5.1.2. Bipolar Disorder
- 5.1.3. Unipolar Disorder
- 5.1.4. Dementia
- 5.1.5. Others
- 5.2. Market Analysis, Insights and Forecast - by Drug Classification
- 5.2.1. First Generation (Typical)
- 5.2.2. Second Generation (Atypical)
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. Asia Pacific
- 5.3.4. Middle East and Africa
- 5.3.5. South America
- 5.1. Market Analysis, Insights and Forecast - by Application
- 6. North America Antipsychotic Drugs Industry Analysis, Insights and Forecast, 2019-2031
- 6.1. Market Analysis, Insights and Forecast - by Application
- 6.1.1. Schizophrenia
- 6.1.2. Bipolar Disorder
- 6.1.3. Unipolar Disorder
- 6.1.4. Dementia
- 6.1.5. Others
- 6.2. Market Analysis, Insights and Forecast - by Drug Classification
- 6.2.1. First Generation (Typical)
- 6.2.2. Second Generation (Atypical)
- 6.1. Market Analysis, Insights and Forecast - by Application
- 7. Europe Antipsychotic Drugs Industry Analysis, Insights and Forecast, 2019-2031
- 7.1. Market Analysis, Insights and Forecast - by Application
- 7.1.1. Schizophrenia
- 7.1.2. Bipolar Disorder
- 7.1.3. Unipolar Disorder
- 7.1.4. Dementia
- 7.1.5. Others
- 7.2. Market Analysis, Insights and Forecast - by Drug Classification
- 7.2.1. First Generation (Typical)
- 7.2.2. Second Generation (Atypical)
- 7.1. Market Analysis, Insights and Forecast - by Application
- 8. Asia Pacific Antipsychotic Drugs Industry Analysis, Insights and Forecast, 2019-2031
- 8.1. Market Analysis, Insights and Forecast - by Application
- 8.1.1. Schizophrenia
- 8.1.2. Bipolar Disorder
- 8.1.3. Unipolar Disorder
- 8.1.4. Dementia
- 8.1.5. Others
- 8.2. Market Analysis, Insights and Forecast - by Drug Classification
- 8.2.1. First Generation (Typical)
- 8.2.2. Second Generation (Atypical)
- 8.1. Market Analysis, Insights and Forecast - by Application
- 9. Middle East and Africa Antipsychotic Drugs Industry Analysis, Insights and Forecast, 2019-2031
- 9.1. Market Analysis, Insights and Forecast - by Application
- 9.1.1. Schizophrenia
- 9.1.2. Bipolar Disorder
- 9.1.3. Unipolar Disorder
- 9.1.4. Dementia
- 9.1.5. Others
- 9.2. Market Analysis, Insights and Forecast - by Drug Classification
- 9.2.1. First Generation (Typical)
- 9.2.2. Second Generation (Atypical)
- 9.1. Market Analysis, Insights and Forecast - by Application
- 10. South America Antipsychotic Drugs Industry Analysis, Insights and Forecast, 2019-2031
- 10.1. Market Analysis, Insights and Forecast - by Application
- 10.1.1. Schizophrenia
- 10.1.2. Bipolar Disorder
- 10.1.3. Unipolar Disorder
- 10.1.4. Dementia
- 10.1.5. Others
- 10.2. Market Analysis, Insights and Forecast - by Drug Classification
- 10.2.1. First Generation (Typical)
- 10.2.2. Second Generation (Atypical)
- 10.1. Market Analysis, Insights and Forecast - by Application
- 11. North America Antipsychotic Drugs Industry Analysis, Insights and Forecast, 2019-2031
- 11.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 11.1.1. undefined
- 12. Europe Antipsychotic Drugs Industry Analysis, Insights and Forecast, 2019-2031
- 12.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 12.1.1. undefined
- 13. Asia Pacific Antipsychotic Drugs Industry Analysis, Insights and Forecast, 2019-2031
- 13.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 13.1.1. undefined
- 14. Middle East and Africa Antipsychotic Drugs Industry Analysis, Insights and Forecast, 2019-2031
- 14.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 14.1.1. undefined
- 15. South America Antipsychotic Drugs Industry Analysis, Insights and Forecast, 2019-2031
- 15.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 15.1.1. undefined
- 16. Competitive Analysis
- 16.1. Global Market Share Analysis 2024
- 16.2. Company Profiles
- 16.2.1 Eli Lily and Company
- 16.2.1.1. Overview
- 16.2.1.2. Products
- 16.2.1.3. SWOT Analysis
- 16.2.1.4. Recent Developments
- 16.2.1.5. Financials (Based on Availability)
- 16.2.2 Sumitomo Pharma Co Ltd
- 16.2.2.1. Overview
- 16.2.2.2. Products
- 16.2.2.3. SWOT Analysis
- 16.2.2.4. Recent Developments
- 16.2.2.5. Financials (Based on Availability)
- 16.2.3 H Lundbeck A/S
- 16.2.3.1. Overview
- 16.2.3.2. Products
- 16.2.3.3. SWOT Analysis
- 16.2.3.4. Recent Developments
- 16.2.3.5. Financials (Based on Availability)
- 16.2.4 Alkermes
- 16.2.4.1. Overview
- 16.2.4.2. Products
- 16.2.4.3. SWOT Analysis
- 16.2.4.4. Recent Developments
- 16.2.4.5. Financials (Based on Availability)
- 16.2.5 Acadia Pharmaceuticals Inc
- 16.2.5.1. Overview
- 16.2.5.2. Products
- 16.2.5.3. SWOT Analysis
- 16.2.5.4. Recent Developments
- 16.2.5.5. Financials (Based on Availability)
- 16.2.6 GlaxoSmithKline plc
- 16.2.6.1. Overview
- 16.2.6.2. Products
- 16.2.6.3. SWOT Analysis
- 16.2.6.4. Recent Developments
- 16.2.6.5. Financials (Based on Availability)
- 16.2.7 Intra-Cellular Therapies Inc
- 16.2.7.1. Overview
- 16.2.7.2. Products
- 16.2.7.3. SWOT Analysis
- 16.2.7.4. Recent Developments
- 16.2.7.5. Financials (Based on Availability)
- 16.2.8 Teva Pharmaceutical Industries Ltd
- 16.2.8.1. Overview
- 16.2.8.2. Products
- 16.2.8.3. SWOT Analysis
- 16.2.8.4. Recent Developments
- 16.2.8.5. Financials (Based on Availability)
- 16.2.9 AstraZeneca plc
- 16.2.9.1. Overview
- 16.2.9.2. Products
- 16.2.9.3. SWOT Analysis
- 16.2.9.4. Recent Developments
- 16.2.9.5. Financials (Based on Availability)
- 16.2.10 AbbVie Inc
- 16.2.10.1. Overview
- 16.2.10.2. Products
- 16.2.10.3. SWOT Analysis
- 16.2.10.4. Recent Developments
- 16.2.10.5. Financials (Based on Availability)
- 16.2.11 Johnson & Johnson
- 16.2.11.1. Overview
- 16.2.11.2. Products
- 16.2.11.3. SWOT Analysis
- 16.2.11.4. Recent Developments
- 16.2.11.5. Financials (Based on Availability)
- 16.2.12 Otsuka Pharmaceutical Co Ltd
- 16.2.12.1. Overview
- 16.2.12.2. Products
- 16.2.12.3. SWOT Analysis
- 16.2.12.4. Recent Developments
- 16.2.12.5. Financials (Based on Availability)
- 16.2.13 Pfizer Inc
- 16.2.13.1. Overview
- 16.2.13.2. Products
- 16.2.13.3. SWOT Analysis
- 16.2.13.4. Recent Developments
- 16.2.13.5. Financials (Based on Availability)
- 16.2.1 Eli Lily and Company
List of Figures
- Figure 1: Global Antipsychotic Drugs Industry Revenue Breakdown (Million, %) by Region 2024 & 2032
- Figure 2: Global Antipsychotic Drugs Industry Volume Breakdown (Dosage, %) by Region 2024 & 2032
- Figure 3: North America Antipsychotic Drugs Industry Revenue (Million), by Country 2024 & 2032
- Figure 4: North America Antipsychotic Drugs Industry Volume (Dosage), by Country 2024 & 2032
- Figure 5: North America Antipsychotic Drugs Industry Revenue Share (%), by Country 2024 & 2032
- Figure 6: North America Antipsychotic Drugs Industry Volume Share (%), by Country 2024 & 2032
- Figure 7: Europe Antipsychotic Drugs Industry Revenue (Million), by Country 2024 & 2032
- Figure 8: Europe Antipsychotic Drugs Industry Volume (Dosage), by Country 2024 & 2032
- Figure 9: Europe Antipsychotic Drugs Industry Revenue Share (%), by Country 2024 & 2032
- Figure 10: Europe Antipsychotic Drugs Industry Volume Share (%), by Country 2024 & 2032
- Figure 11: Asia Pacific Antipsychotic Drugs Industry Revenue (Million), by Country 2024 & 2032
- Figure 12: Asia Pacific Antipsychotic Drugs Industry Volume (Dosage), by Country 2024 & 2032
- Figure 13: Asia Pacific Antipsychotic Drugs Industry Revenue Share (%), by Country 2024 & 2032
- Figure 14: Asia Pacific Antipsychotic Drugs Industry Volume Share (%), by Country 2024 & 2032
- Figure 15: Middle East and Africa Antipsychotic Drugs Industry Revenue (Million), by Country 2024 & 2032
- Figure 16: Middle East and Africa Antipsychotic Drugs Industry Volume (Dosage), by Country 2024 & 2032
- Figure 17: Middle East and Africa Antipsychotic Drugs Industry Revenue Share (%), by Country 2024 & 2032
- Figure 18: Middle East and Africa Antipsychotic Drugs Industry Volume Share (%), by Country 2024 & 2032
- Figure 19: South America Antipsychotic Drugs Industry Revenue (Million), by Country 2024 & 2032
- Figure 20: South America Antipsychotic Drugs Industry Volume (Dosage), by Country 2024 & 2032
- Figure 21: South America Antipsychotic Drugs Industry Revenue Share (%), by Country 2024 & 2032
- Figure 22: South America Antipsychotic Drugs Industry Volume Share (%), by Country 2024 & 2032
- Figure 23: North America Antipsychotic Drugs Industry Revenue (Million), by Application 2024 & 2032
- Figure 24: North America Antipsychotic Drugs Industry Volume (Dosage), by Application 2024 & 2032
- Figure 25: North America Antipsychotic Drugs Industry Revenue Share (%), by Application 2024 & 2032
- Figure 26: North America Antipsychotic Drugs Industry Volume Share (%), by Application 2024 & 2032
- Figure 27: North America Antipsychotic Drugs Industry Revenue (Million), by Drug Classification 2024 & 2032
- Figure 28: North America Antipsychotic Drugs Industry Volume (Dosage), by Drug Classification 2024 & 2032
- Figure 29: North America Antipsychotic Drugs Industry Revenue Share (%), by Drug Classification 2024 & 2032
- Figure 30: North America Antipsychotic Drugs Industry Volume Share (%), by Drug Classification 2024 & 2032
- Figure 31: North America Antipsychotic Drugs Industry Revenue (Million), by Country 2024 & 2032
- Figure 32: North America Antipsychotic Drugs Industry Volume (Dosage), by Country 2024 & 2032
- Figure 33: North America Antipsychotic Drugs Industry Revenue Share (%), by Country 2024 & 2032
- Figure 34: North America Antipsychotic Drugs Industry Volume Share (%), by Country 2024 & 2032
- Figure 35: Europe Antipsychotic Drugs Industry Revenue (Million), by Application 2024 & 2032
- Figure 36: Europe Antipsychotic Drugs Industry Volume (Dosage), by Application 2024 & 2032
- Figure 37: Europe Antipsychotic Drugs Industry Revenue Share (%), by Application 2024 & 2032
- Figure 38: Europe Antipsychotic Drugs Industry Volume Share (%), by Application 2024 & 2032
- Figure 39: Europe Antipsychotic Drugs Industry Revenue (Million), by Drug Classification 2024 & 2032
- Figure 40: Europe Antipsychotic Drugs Industry Volume (Dosage), by Drug Classification 2024 & 2032
- Figure 41: Europe Antipsychotic Drugs Industry Revenue Share (%), by Drug Classification 2024 & 2032
- Figure 42: Europe Antipsychotic Drugs Industry Volume Share (%), by Drug Classification 2024 & 2032
- Figure 43: Europe Antipsychotic Drugs Industry Revenue (Million), by Country 2024 & 2032
- Figure 44: Europe Antipsychotic Drugs Industry Volume (Dosage), by Country 2024 & 2032
- Figure 45: Europe Antipsychotic Drugs Industry Revenue Share (%), by Country 2024 & 2032
- Figure 46: Europe Antipsychotic Drugs Industry Volume Share (%), by Country 2024 & 2032
- Figure 47: Asia Pacific Antipsychotic Drugs Industry Revenue (Million), by Application 2024 & 2032
- Figure 48: Asia Pacific Antipsychotic Drugs Industry Volume (Dosage), by Application 2024 & 2032
- Figure 49: Asia Pacific Antipsychotic Drugs Industry Revenue Share (%), by Application 2024 & 2032
- Figure 50: Asia Pacific Antipsychotic Drugs Industry Volume Share (%), by Application 2024 & 2032
- Figure 51: Asia Pacific Antipsychotic Drugs Industry Revenue (Million), by Drug Classification 2024 & 2032
- Figure 52: Asia Pacific Antipsychotic Drugs Industry Volume (Dosage), by Drug Classification 2024 & 2032
- Figure 53: Asia Pacific Antipsychotic Drugs Industry Revenue Share (%), by Drug Classification 2024 & 2032
- Figure 54: Asia Pacific Antipsychotic Drugs Industry Volume Share (%), by Drug Classification 2024 & 2032
- Figure 55: Asia Pacific Antipsychotic Drugs Industry Revenue (Million), by Country 2024 & 2032
- Figure 56: Asia Pacific Antipsychotic Drugs Industry Volume (Dosage), by Country 2024 & 2032
- Figure 57: Asia Pacific Antipsychotic Drugs Industry Revenue Share (%), by Country 2024 & 2032
- Figure 58: Asia Pacific Antipsychotic Drugs Industry Volume Share (%), by Country 2024 & 2032
- Figure 59: Middle East and Africa Antipsychotic Drugs Industry Revenue (Million), by Application 2024 & 2032
- Figure 60: Middle East and Africa Antipsychotic Drugs Industry Volume (Dosage), by Application 2024 & 2032
- Figure 61: Middle East and Africa Antipsychotic Drugs Industry Revenue Share (%), by Application 2024 & 2032
- Figure 62: Middle East and Africa Antipsychotic Drugs Industry Volume Share (%), by Application 2024 & 2032
- Figure 63: Middle East and Africa Antipsychotic Drugs Industry Revenue (Million), by Drug Classification 2024 & 2032
- Figure 64: Middle East and Africa Antipsychotic Drugs Industry Volume (Dosage), by Drug Classification 2024 & 2032
- Figure 65: Middle East and Africa Antipsychotic Drugs Industry Revenue Share (%), by Drug Classification 2024 & 2032
- Figure 66: Middle East and Africa Antipsychotic Drugs Industry Volume Share (%), by Drug Classification 2024 & 2032
- Figure 67: Middle East and Africa Antipsychotic Drugs Industry Revenue (Million), by Country 2024 & 2032
- Figure 68: Middle East and Africa Antipsychotic Drugs Industry Volume (Dosage), by Country 2024 & 2032
- Figure 69: Middle East and Africa Antipsychotic Drugs Industry Revenue Share (%), by Country 2024 & 2032
- Figure 70: Middle East and Africa Antipsychotic Drugs Industry Volume Share (%), by Country 2024 & 2032
- Figure 71: South America Antipsychotic Drugs Industry Revenue (Million), by Application 2024 & 2032
- Figure 72: South America Antipsychotic Drugs Industry Volume (Dosage), by Application 2024 & 2032
- Figure 73: South America Antipsychotic Drugs Industry Revenue Share (%), by Application 2024 & 2032
- Figure 74: South America Antipsychotic Drugs Industry Volume Share (%), by Application 2024 & 2032
- Figure 75: South America Antipsychotic Drugs Industry Revenue (Million), by Drug Classification 2024 & 2032
- Figure 76: South America Antipsychotic Drugs Industry Volume (Dosage), by Drug Classification 2024 & 2032
- Figure 77: South America Antipsychotic Drugs Industry Revenue Share (%), by Drug Classification 2024 & 2032
- Figure 78: South America Antipsychotic Drugs Industry Volume Share (%), by Drug Classification 2024 & 2032
- Figure 79: South America Antipsychotic Drugs Industry Revenue (Million), by Country 2024 & 2032
- Figure 80: South America Antipsychotic Drugs Industry Volume (Dosage), by Country 2024 & 2032
- Figure 81: South America Antipsychotic Drugs Industry Revenue Share (%), by Country 2024 & 2032
- Figure 82: South America Antipsychotic Drugs Industry Volume Share (%), by Country 2024 & 2032
List of Tables
- Table 1: Global Antipsychotic Drugs Industry Revenue Million Forecast, by Region 2019 & 2032
- Table 2: Global Antipsychotic Drugs Industry Volume Dosage Forecast, by Region 2019 & 2032
- Table 3: Global Antipsychotic Drugs Industry Revenue Million Forecast, by Application 2019 & 2032
- Table 4: Global Antipsychotic Drugs Industry Volume Dosage Forecast, by Application 2019 & 2032
- Table 5: Global Antipsychotic Drugs Industry Revenue Million Forecast, by Drug Classification 2019 & 2032
- Table 6: Global Antipsychotic Drugs Industry Volume Dosage Forecast, by Drug Classification 2019 & 2032
- Table 7: Global Antipsychotic Drugs Industry Revenue Million Forecast, by Region 2019 & 2032
- Table 8: Global Antipsychotic Drugs Industry Volume Dosage Forecast, by Region 2019 & 2032
- Table 9: Global Antipsychotic Drugs Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 10: Global Antipsychotic Drugs Industry Volume Dosage Forecast, by Country 2019 & 2032
- Table 11: Global Antipsychotic Drugs Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 12: Global Antipsychotic Drugs Industry Volume Dosage Forecast, by Country 2019 & 2032
- Table 13: Global Antipsychotic Drugs Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 14: Global Antipsychotic Drugs Industry Volume Dosage Forecast, by Country 2019 & 2032
- Table 15: Global Antipsychotic Drugs Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 16: Global Antipsychotic Drugs Industry Volume Dosage Forecast, by Country 2019 & 2032
- Table 17: Global Antipsychotic Drugs Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 18: Global Antipsychotic Drugs Industry Volume Dosage Forecast, by Country 2019 & 2032
- Table 19: Global Antipsychotic Drugs Industry Revenue Million Forecast, by Application 2019 & 2032
- Table 20: Global Antipsychotic Drugs Industry Volume Dosage Forecast, by Application 2019 & 2032
- Table 21: Global Antipsychotic Drugs Industry Revenue Million Forecast, by Drug Classification 2019 & 2032
- Table 22: Global Antipsychotic Drugs Industry Volume Dosage Forecast, by Drug Classification 2019 & 2032
- Table 23: Global Antipsychotic Drugs Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 24: Global Antipsychotic Drugs Industry Volume Dosage Forecast, by Country 2019 & 2032
- Table 25: United States Antipsychotic Drugs Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 26: United States Antipsychotic Drugs Industry Volume (Dosage) Forecast, by Application 2019 & 2032
- Table 27: Canada Antipsychotic Drugs Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 28: Canada Antipsychotic Drugs Industry Volume (Dosage) Forecast, by Application 2019 & 2032
- Table 29: Mexico Antipsychotic Drugs Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 30: Mexico Antipsychotic Drugs Industry Volume (Dosage) Forecast, by Application 2019 & 2032
- Table 31: Global Antipsychotic Drugs Industry Revenue Million Forecast, by Application 2019 & 2032
- Table 32: Global Antipsychotic Drugs Industry Volume Dosage Forecast, by Application 2019 & 2032
- Table 33: Global Antipsychotic Drugs Industry Revenue Million Forecast, by Drug Classification 2019 & 2032
- Table 34: Global Antipsychotic Drugs Industry Volume Dosage Forecast, by Drug Classification 2019 & 2032
- Table 35: Global Antipsychotic Drugs Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 36: Global Antipsychotic Drugs Industry Volume Dosage Forecast, by Country 2019 & 2032
- Table 37: Germany Antipsychotic Drugs Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 38: Germany Antipsychotic Drugs Industry Volume (Dosage) Forecast, by Application 2019 & 2032
- Table 39: United Kingdom Antipsychotic Drugs Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 40: United Kingdom Antipsychotic Drugs Industry Volume (Dosage) Forecast, by Application 2019 & 2032
- Table 41: France Antipsychotic Drugs Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 42: France Antipsychotic Drugs Industry Volume (Dosage) Forecast, by Application 2019 & 2032
- Table 43: Italy Antipsychotic Drugs Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 44: Italy Antipsychotic Drugs Industry Volume (Dosage) Forecast, by Application 2019 & 2032
- Table 45: Spain Antipsychotic Drugs Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 46: Spain Antipsychotic Drugs Industry Volume (Dosage) Forecast, by Application 2019 & 2032
- Table 47: Rest of Europe Antipsychotic Drugs Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 48: Rest of Europe Antipsychotic Drugs Industry Volume (Dosage) Forecast, by Application 2019 & 2032
- Table 49: Global Antipsychotic Drugs Industry Revenue Million Forecast, by Application 2019 & 2032
- Table 50: Global Antipsychotic Drugs Industry Volume Dosage Forecast, by Application 2019 & 2032
- Table 51: Global Antipsychotic Drugs Industry Revenue Million Forecast, by Drug Classification 2019 & 2032
- Table 52: Global Antipsychotic Drugs Industry Volume Dosage Forecast, by Drug Classification 2019 & 2032
- Table 53: Global Antipsychotic Drugs Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 54: Global Antipsychotic Drugs Industry Volume Dosage Forecast, by Country 2019 & 2032
- Table 55: China Antipsychotic Drugs Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 56: China Antipsychotic Drugs Industry Volume (Dosage) Forecast, by Application 2019 & 2032
- Table 57: Japan Antipsychotic Drugs Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 58: Japan Antipsychotic Drugs Industry Volume (Dosage) Forecast, by Application 2019 & 2032
- Table 59: India Antipsychotic Drugs Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 60: India Antipsychotic Drugs Industry Volume (Dosage) Forecast, by Application 2019 & 2032
- Table 61: Australia Antipsychotic Drugs Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 62: Australia Antipsychotic Drugs Industry Volume (Dosage) Forecast, by Application 2019 & 2032
- Table 63: South Korea Antipsychotic Drugs Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 64: South Korea Antipsychotic Drugs Industry Volume (Dosage) Forecast, by Application 2019 & 2032
- Table 65: Rest of Asia Pacific Antipsychotic Drugs Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 66: Rest of Asia Pacific Antipsychotic Drugs Industry Volume (Dosage) Forecast, by Application 2019 & 2032
- Table 67: Global Antipsychotic Drugs Industry Revenue Million Forecast, by Application 2019 & 2032
- Table 68: Global Antipsychotic Drugs Industry Volume Dosage Forecast, by Application 2019 & 2032
- Table 69: Global Antipsychotic Drugs Industry Revenue Million Forecast, by Drug Classification 2019 & 2032
- Table 70: Global Antipsychotic Drugs Industry Volume Dosage Forecast, by Drug Classification 2019 & 2032
- Table 71: Global Antipsychotic Drugs Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 72: Global Antipsychotic Drugs Industry Volume Dosage Forecast, by Country 2019 & 2032
- Table 73: GCC Antipsychotic Drugs Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 74: GCC Antipsychotic Drugs Industry Volume (Dosage) Forecast, by Application 2019 & 2032
- Table 75: South Africa Antipsychotic Drugs Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 76: South Africa Antipsychotic Drugs Industry Volume (Dosage) Forecast, by Application 2019 & 2032
- Table 77: Rest of Middle East and Africa Antipsychotic Drugs Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 78: Rest of Middle East and Africa Antipsychotic Drugs Industry Volume (Dosage) Forecast, by Application 2019 & 2032
- Table 79: Global Antipsychotic Drugs Industry Revenue Million Forecast, by Application 2019 & 2032
- Table 80: Global Antipsychotic Drugs Industry Volume Dosage Forecast, by Application 2019 & 2032
- Table 81: Global Antipsychotic Drugs Industry Revenue Million Forecast, by Drug Classification 2019 & 2032
- Table 82: Global Antipsychotic Drugs Industry Volume Dosage Forecast, by Drug Classification 2019 & 2032
- Table 83: Global Antipsychotic Drugs Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 84: Global Antipsychotic Drugs Industry Volume Dosage Forecast, by Country 2019 & 2032
- Table 85: Brazil Antipsychotic Drugs Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 86: Brazil Antipsychotic Drugs Industry Volume (Dosage) Forecast, by Application 2019 & 2032
- Table 87: Argentina Antipsychotic Drugs Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 88: Argentina Antipsychotic Drugs Industry Volume (Dosage) Forecast, by Application 2019 & 2032
- Table 89: Rest of South America Antipsychotic Drugs Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 90: Rest of South America Antipsychotic Drugs Industry Volume (Dosage) Forecast, by Application 2019 & 2032
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Antipsychotic Drugs Industry?
The projected CAGR is approximately 5.60%.
2. Which companies are prominent players in the Antipsychotic Drugs Industry?
Key companies in the market include Eli Lily and Company, Sumitomo Pharma Co Ltd, H Lundbeck A/S, Alkermes, Acadia Pharmaceuticals Inc, GlaxoSmithKline plc, Intra-Cellular Therapies Inc, Teva Pharmaceutical Industries Ltd, AstraZeneca plc, AbbVie Inc, Johnson & Johnson, Otsuka Pharmaceutical Co Ltd, Pfizer Inc.
3. What are the main segments of the Antipsychotic Drugs Industry?
The market segments include Application, Drug Classification.
4. Can you provide details about the market size?
The market size is estimated to be USD XX Million as of 2022.
5. What are some drivers contributing to market growth?
Rising Prevalence of Mental Disorders; Increasing Focus of Governments and Health Care Organizations on Mental Health; Constant Investment in Research and Development.
6. What are the notable trends driving market growth?
Schizophrenia is Expected to Hold Major Share in the Market over the Forecast Period.
7. Are there any restraints impacting market growth?
Addiction Caused Due to the Antipsychotic Drugs; Patent Expiry of Major Drugs.
8. Can you provide examples of recent developments in the market?
In January 2023, Luye Pharma Group received the Food and Drug Administration approval for Rykindo with the aim to treat Schizophrenia and bipolar 1 disorder.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million and volume, measured in Dosage.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Antipsychotic Drugs Industry," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Antipsychotic Drugs Industry report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Antipsychotic Drugs Industry?
To stay informed about further developments, trends, and reports in the Antipsychotic Drugs Industry, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database



Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)

Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations

Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence